Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026

Contributed by: PR Newswire

Tags

HANSA-ConfIdeS-ATC

More Like This

Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patients

Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients